Cello Therapeutics, Inc. (Cello) is a leading biomedical company focused on developing novel nanoparticle delivery platforms for cancer treatment. Our cellular nanoparticles (CNPs) are comprised of three main components—drug payload, biocompatible polymer, and natural cellular membrane. The payload could be a chemotherapy or immunomodulatory agent, mRNA or siRNA. The drugs are loaded within the biodegradable polymer core, which is then coated with membrane derived from human cells. This cell membrane coating technology is a recent breakthrough in the field of nanomedicine. Our target is to treat all types of cancers with a single delivery platform. In vitro and in vivo studies suggest that these biomimetic nanoparticles significantly improve the performance of chemotherapy, immunotherapy, and improve the delivery of mRNA an siRNA to tumor sites. One of our immunotherapy nanoparticle formulations has increased the cancer survival rate to 85-100% in a mouse cancer model in repeated in vivo studies. In animal studies, the delivery of mRNA and siRNA via CNP platform increases efficiency over 10 times and 7 times, respectively.
Founded in 2016 in San Diego, CA, Cello has been committed to saving patients’ lives. We keep cancer patients in our hearts as we relentlessly develop and test new formulations that improve upon current cancer therapies. Our objective is to accelerate the process of delivering novel and effective medical treatments to cancer patients’ hands.
On November 30, 2023, Cello Therapeutics, Inc. received IND clearance from the U.S. Food and Drug Administration (FDA) for its first immunotherapy nanoformulation CE120 to initiate first-in-human clinical trials for a variety of solid tumors.
